Business Wire

Servier announce updated overall survival results of exploratory TASCO1 phase II study of LONSURF ® + bevacizumab in a first-line setting for patients with unresectable mCRC non-eligible for intensive therapy

Share

Servier announced today updated results from the exploratory phase II TASCO1 study evaluating LONSURF® (trifluridine/tipiracil) + bevacizumab and capecitabine + bevacizumab (C-B) in a first-line setting for patients with unresectable metastatic colorectal cancer (mCRC) who are non-eligible for intensive therapy.1 The data were announced today during an oral presentation at the 2021 ASCO Gastrointestinal Cancers Symposium (ASCO-GI). Patients with mCRC who are not eligible for chemotherapy face a large unmet need, with fewer treatment options available to them and lower survival rates.

Colorectal cancer (CRC) makes up 9.7% of total global cancer cases, with almost 1.4 million new cases of CRC each year.2 In Europe, CRC is the second most common cause of death due to cancer, and those with a metastatic disease have a 5-year survival rate of just 11%.3

“For patients with metastatic colorectal cancer, those non-eligible for standard combination therapy have few options left and we are continuously searching for new ways to give these patients more hope,” said Professor Eric Van Cutsem, Leuven, Belgium “The data from TASCO1 are very encouraging and provide evidence that trifluridine/tipiracil + bevacizumab is a beneficial treatment combination for these patients.”

In the exploratory phase II TASCO1 study, 153 patients were randomized and followed until September 1, 2020.1 The updated results showed that the median overall survival (OS) was 22.3 months with LONSURF + bevacizumab, whereas it was 17.6 months with C-B. This data translates into an improved median OS of 4.6 months with LONSURF + bevacizumab when compared with C-B (HR, 0.78; 95% CI, 0.55, 1.10). The survival probability at 18 months with LONSURF + bevacizumab was 0.62 (95% CI, 0.50, 0.72) and 0.47 (95% CI, 0.35, 0.57) with C-B.1 It should be noted that this was an exploratory, non-comparative study.

“We are very pleased with the updated results from the phase II TASCO1 study and we are continuing with our research into this promising combination in multiple mCRC settings. These data support all efforts that went into the confirmatory phase III SOLSTICE study. The results are expected in 2021,” said Patrick Therasse, M.D., Ph. D., Head of Servier Late Stage and Life Cycle Management Oncology, “Patients with mCRC who are not eligible for intensive chemotherapy have limited options and further clinical trials for additional treatments are highly anticipated by the clinical and patient communities alike.”

#ENDS#

About TASCO1

TASCO1 is an open-label, randomized, non-comparative Phase II study evaluating LONSURF® + bevacizumab and capecitabine plus bevacizumab in patients with previously untreated metastatic colorectal cancer who are non-eligible for intensive therapy. From April 2016 to March 2017, 153 patients were randomized and followed until end-of-study on September 1, 2020. The primary endpoint was progression-free survival, and the key secondary endpoint was overall survival.

For more information on TASCO1, please visit www.ClinicalTrials.gov (https://www.clinicaltrials.gov/ct2/show/NCT02743221). The ClinicalTrials.gov Identifier is NCT02743221.

About SOLSTICE

SOLSTICE is an open-label, randomized, multicentre Phase III trial in 854 unresectable metastatic colorectal cancer patients who are not candidates for, or do not require, intensive therapy. Patients were randomized 1:1 to receive first-line LONSURF® + bevacizumab versus capecitabine + bevacizumab. The primary objective is to demonstrate superior progression-free survival with LONSURF® + bevacizumab over capecitabine + bevacizumab. The first patient was enrolled in March 2019. Results are expected in 2021.

For more information on SOLSTICE, please visit www.ClinicalTrials.gov (https://www.clinicaltrials.gov/ct2/show/NCT03869892). The ClinicalTrials.gov Identifier is NCT03869892.

About Metastatic Colorectal Cancer (mCRC)

Colorectal cancer is the third most common cancer worldwide with approximately 1.8 million new diagnoses in 2018. Each year there are over 880,000 deaths, making it the second biggest cancer killer worldwide (after lung cancer).3

For those with metastatic disease (where the cancer has spread from the primary site), the average 5-year survival is approximately 11%.4 Standard chemotherapy regimens for advanced mCRC include fluoropyrimidines, oxaliplatin, irinotecan or targeted treatments, such as those that target vascular endothelial growth factors (VEGF) or endothelial growth factor receptors (EGFR).

Over the last decade, clinical outcomes for patients with mCRC have improved considerably due to the advent of novel treatment agents, predictive biomarkers, and a more strategic approach to the delivery of systemic therapies. Currently, the median overall survival for patients with mCRC being treated both in phase III trials and in large observational series or registries is 30 months – more than double that of 20 years ago.5,6,7

About LONSURF®8

LONSURF® consists of a thymidine-based nucleoside analog, trifluridine, and the thymidine phosphorylase (TP) inhibitor, tipiracil, which increases trifluridine exposure by inhibiting its metabolism by TP. Trifluridine is incorporated into DNA, resulting in DNA dysfunction and inhibition of cell proliferation.

In the EU, LONSURF® is indicated as monotherapy for the treatment of adult patients with metastatic colorectal cancer (CRC) who have been previously treated with, or are not considered candidates for, available therapies including fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapies, anti- VEGF agents, and anti-EGFR agents. LONSURF® is also indicated as monotherapy for the treatment of adult patients with metastatic gastric cancer (mGC), including adenocarcinoma of the gastroesophageal junction (mGEJC), who have been previously treated with at least two prior systemic treatment regimens for advanced disease.

As of November 2020, LONSURF® has been approved in 91 countries for the treatment of advanced mCRC and in 56 countries for the treatment of advanced mGC/mGEJC.

LONSURF® was discovered and developed by Taiho Pharmaceutical. In June 2015, Taiho Pharmaceutical and Servier entered into an exclusive license agreement for the co-development and commercialization of LONSURF® in Europe and other countries outside of the United States, Canada, Mexico, and Asia.

About Servier

Servier is an international pharmaceutical company governed by a non-profit foundation, with its headquarters in France (Suresnes). With a strong international presence in 150 countries and a total revenue of 4.6 billion euros in 2019, Servier employs 22,000 people worldwide. Entirely independent, the Group invests on average 25% of its total revenue (excluding generics) every year in research and development and uses all its profits for its development. Corporate growth is driven by Servier’s constant commitment in five areas of excellence: cardiovascular, immune-inflammatory, and neurodegenerative diseases, cancer and diabetes, as well as by its activities in high-quality generic drugs. Servier also offers eHealth solutions beyond drug development. More information: www.servier.com

Follow us on Social Media:

LinkedIn

Facebook

Twitter


1 Van Cutsem E, Danielewicz I, Saunders MP, et al. Phase II study evaluating trifluridine/tipiracil + bevacizumab and capecitabine + bevacizumab in first-line unresectable metastatic colorectal cancer (mCRC) patients who are non-eligible for intensive therapy (TASCO1): results of the final analysis on the overall survival. ASCO GI 2021.

2 Digestive Cancers Europe. Prevalence of Colorectal Cancer. https://digestivecancers.eu/colorectal-cancer/prevalence-of-colorectal-cancer-prevalence/?menu_id=13873 Last accessed December 2020.

3 World Health Organisation. GLOBOCAN. Cancer today. Estimated age-standardized incidence rates (World) in 2018, all cancers, both sexes, all ages. https://gco.iarc.fr/today/online-analysis-map?v=2018&mode=population&mode_population=continents&population=900&populations=900&key=asr&sex=0&cancer=39&type=0&statistic=5&prevalence=0&population_group=0&ages_group%5B%5D=0&ages_group%5B%5D=17&nb_items=10&group_cancer=1&include_nmsc=1&include_nmsc_other=1&projection=natural-earth&color_palette=default&map_scale=quantile&map_nb_colors=5&continent=0&rotate=%255B10%252C0%255D Last accessed May 2020.

4 American Cancer Society. Survival Rates for Colorectal Cancer, by Stage. https://www.cancer.org/cancer/colon-rectal-cancer/detection-diagnosis-staging/survival-rates.html Last accessed December 2020.

5 Brenner H, Kloor M, Pox CP. Colorectal cancer. Lancet (London, England). 2014;383(9927):1490-1502.

6 Price TJ, Segelov E, Burge M, et al. Current opinion on optimal systemic treatment for metastatic colorectal cancer: outcome of the ACTG/AGITG expert meeting ECCO 2013. Expert Rev Anticancer Ther. 2014;14(12):1477-1493.

7 Van Cutsem E, Cervantes A, Adam R, et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol. 2016;27(8):1386-1422.

8 European Medicines Agency. LONSURF European Public assessment report. https://www.ema.europa.eu/en/medicines/human/EPAR/LONSURF#authorisation-details-section Last accessed December 2020.

Contact information

Servier Media Relations
Sonia Marques:
presse@servier.com
Tel. +33 (0)1 55 72 40 21 / + 33 (0) 7 84 28 76 13

Jean-Clément Vergeau:
presse@servier.com
Tel. +33 (0)1 55 72 46 16 / + 33 (0) 6 79 56 75 96

About Business Wire

Business Wire
Business Wire



Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Hologic Acquires European Molecular Diagnostic Company Diagenode for Approximately $159 Million1.3.2021 13:00:00 CETPress release

Hologic, Inc. (Nasdaq: HOLX), a global leader in women's health, announced today that it has acquired Diagenode, a privately held, European developer and manufacturer of molecular diagnostic assays and epigenetics products, for approximately $159 million (130 million euros), subject to working capital and other customary closing adjustments. “Acquiring Diagenode further strengthens our molecular diagnostics business by expanding our international capabilities, improving our regional time-to-market, and allowing us to offer a broader, more differentiated test menu,” said Jan Verstreken, Hologic’s group president, international. “Diagenode has been a great partner since 2016, helping us develop and manufacture PCR-based assays for Panther Fusion®. Now we look forward to accelerating and broadening those efforts to benefit our customers and patients.” Diagenode offers more than 30 real-time PCR (polymerase chain reaction) tests that are CE-marked for the detection of bacteria, parasites a

Mouser Electronics Releases New Intelligent Revolution eBook Examining AI in Humanitarian Applications1.3.2021 13:00:00 CETPress release

Mouser Electronics Inc. today released Artificial Intelligence: Improving Harvests and the Human Experience, the third eBook from The Intelligent Revolution series. The new eBook examines fascinating new uses for artificial intelligence (AI) in farming and other specialised applications targeting the human experience. Mouser’s AI-focused eBook series is part of the company’s award-winning Empowering Innovation Together program. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210301005097/en/ Mouser Electronics announces the third eBook from The Intelligent Revolution series, which examines fascinating new uses for AI in farming and other applications to improve the human experience. (Graphic: Business Wire) “While many are familiar with some common uses for artificial intelligence, innovative scientists around the world are constantly finding new applications,” said Kevin Hess, Senior Vice President, Marketing at Mouser Elect

Market Survey by TSUNO Group Reveals “Rice Bran Oil” Market in Japan Is Expanding Under COVID-19 Pandemic1.3.2021 11:35:00 CETPress release

TSUNO Group (HQ: Wakayama, Japan https://www.tsuno.co.jp) surveys the sales figure of edible vegetable oils and rice bran oil in Japan. (Data of The Nikkei 64 major chains stores and 461 stores in Japan March to May result based on total sales). As a result, the market of Rice Bran Oil for household use has expanded by 42% compared to the previous year. While the vegetable oil sales increased by 11% from previous year, rice bran oil and sesame oil sales grew by 42% during a state of emergency in Japan. The rapid expansion of these two oils could be explained by a rise in people’s health-consciousness under COVID-19 pandemic. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210301005397/en/ TSUNO brand rice bran oils sized from 180g to 1500g. Full nutrients from rice bran are contained. Rice Bran Oil has strong anti oxidant effect and its healthy and goes well with any kind of dishes from dressing to deep fries. (Photo: Busines

Visa’s Mission to Digitally Enable Small Businesses Gains Momentum Across Europe1.3.2021 10:00:00 CETPress release

Visa (NYSE: V) today announced more than 100 partners across Europe have joined the Where You Shop Matters initiative to help small business owners build digital capabilities and continue serving their communities. More than two million small firms across Europe have received support since the launch of the program in summer 2020. The announcement marks a major milestone in Visa’s commitment to help eight million small and medium sized businesses (SMBs) in Europe – and 50 million globally - to get online, adapt and future proof their business. Across Europe, Covid-19 continues to have a devastating impact on small businesses. Research conducted by Visa revealed that 65% of small businesses are concerned about the future of their business.1 With many having to operate under restrictions and lockdowns, small businesses are increasingly moving their operations online and embracing digital payments. Visa data shows that over 10 countries in Europe have seen a 20% increase in online sales a

Northern Trust Asset Management’s FlexShares ® Enters European ETF Market1.3.2021 10:00:00 CETPress release

Northern Trust Asset Management’s FlexShares Exchange Traded Funds today announced the launch of two climate focused exchange traded funds (ETFs): the FlexShares® Developed Markets Low Volatility Climate ESG UCITS ETF (QVFD) and the FlexShares® Developed Market High Dividend Climate ESG UCITS ETF (QDFD). The Funds represent FlexShares’ first ETFs available in Europe, with additional funds planned to launch in the coming months. “We’re pleased to present the first FlexShares products in Europe, which reflect Northern Trust Asset Management’s three decades of experience in managing sustainability-focused investment strategies,” said Marie Dzanis, head of Europe, Middle East and Africa (EMEA). “Actively designed with the transparency of indexing, these two ETFs are built specifically to fit within EMEA investors’ evolving needs to help manage portfolio volatility and deliver income in a low yield environment while doing so with a focus on quality.” Both strategies will utilize Northern Tr

Effissimo Releases Presentation Explaining Proposal to Appoint Independent Investigators at Toshiba1.3.2021 08:00:00 CETPress release

Effissimo Capital Management (“Effissimo”), the largest shareholder of Toshiba Corporation (“Toshiba”) (TYO:6502) through the funds it manages, today released a presentation explaining the reasons behind its proposal for an independent investigation into reported irregularities surrounding Toshiba’s July 2020 Annual General Meeting of Shareholders (“AGM”). Effissimo’s proposal will be voted on by Toshiba’s shareholders at an extraordinary shareholders meeting scheduled for March 18, 2021. The full proposal in English can be found here. Supplementing its letter to shareholders dated February 24, 2021, Effissimo’s presentation explains its proposal for an independent investigation into the irregular handling of shareholder voting and shareholder pressure at the closely contested AGM, which Toshiba’s conflicted Audit Committee’s self-audit fails to address. The presentation provides data showing discrepancies in the claimed delivery times of mailed ballots said by Toshiba’s vote tabulator

Mobidiag Receives CE-IVD Marking for Amplidiag ® RESP-4 for Simultaneous Detection of COVID-19, Flu A, Flu B and RSV1.3.2021 07:00:00 CETPress release

Mobidiag Ltd. today announces that it has received CE-IVD marking for its https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fmobidiag.com%2Fproducts%2Famplidiag%2F%23ad-resp-4&esheet=52387757&newsitemid=20210228005031&lan=en-US&anchor=Amplidiag%26%23174%3B+RESP-4&index=1&md5=0cd23e123f09386349b0cce93993cf54 Amplidiag® RESP-4 molecular diagnostic test for the rapid and simultaneous detection of some of the most prevalent respiratory viruses: SARS-CoV-2 (responsible for COVID-19 infection), Influenza A, Influenza B and RSV. These viruses present similar symptoms, making it difficult for physicians to determine accurately which virus a patient has. The https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fmobidiag.com%2Fproducts%2Famplidiag%2F%23ad-resp-4&esheet=52387757&newsitemid=20210228005031&lan=en-US&anchor=Amplidiag%26%23174%3B+RESP-4&index=2&md5=464a0549cf8a17c939d070d2af83d1a7 Amplidiag® RESP-4 assay can rapidly and simultaneously determine an accurate

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom